{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:14:15Z","timestamp":1791490455855,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["NIA R01AG046171"],"award-info":[{"award-number":["NIA R01AG046171"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG051550"],"award-info":[{"award-number":["RF1AG051550"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG057452"],"award-info":[{"award-number":["RF1AG057452"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG059093"],"award-info":[{"award-number":["R01AG059093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG058942"],"award-info":[{"award-number":["RF1AG058942"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AG061359"],"award-info":[{"award-number":["U01AG061359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AG063744"],"award-info":[{"award-number":["U19AG063744"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["DAOU16AMPA"],"award-info":[{"award-number":["DAOU16AMPA"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006528","name":"Alzheimer's Disease Research Center, Emory University","doi-asserted-by":"publisher","award":["P30 AG066511"],"award-info":[{"award-number":["P30 AG066511"]}],"id":[{"id":"10.13039\/100006528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","award":["R01 AG070937"],"award-info":[{"award-number":["R01 AG070937"]}],"id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007917","name":"Agricultural Research Service","doi-asserted-by":"publisher","award":["2032-51530-022-00D"],"award-info":[{"award-number":["2032-51530-022-00D"]}],"id":[{"id":"10.13039\/100007917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007917","name":"Agricultural Research Service","doi-asserted-by":"publisher","award":["2032-51530-025-00D"],"award-info":[{"award-number":["2032-51530-025-00D"]}],"id":[{"id":"10.13039\/100007917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease, cardiovascular disease, and other cardiometabolic disorders may share inflammatory origins. Lipid mediators, including oxylipins, endocannabinoids, bile acids, and steroids, regulate inflammation, energy metabolism, and cell proliferation with well-established involvement in cardiometabolic diseases. However, their role in Alzheimer\u2019s disease is poorly understood. Here, we describe the analysis of plasma and cerebrospinal fluid lipid mediators in a case\u2013control comparison of ~150 individuals with Alzheimer\u2019s disease and ~135 healthy controls, to investigate this knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Lipid mediators were measured using targeted quantitative mass spectrometry. Data were analyzed using the analysis of covariates, adjusting for sex, age, and ethnicity. Partial least square discriminant analysis identified plasma and cerebrospinal fluid lipid mediator discriminates of Alzheimer\u2019s disease. Alzheimer\u2019s disease predictive models were constructed using machine learning combined with stepwise logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both plasma and cerebrospinal fluid, individuals with Alzheimer\u2019s disease had elevated cytochrome P450\/soluble epoxide hydrolase pathway components and decreased fatty acid ethanolamides compared to healthy controls. Circulating metabolites of soluble epoxide hydrolase and ethanolamides provide Alzheimer\u2019s disease predictors with areas under receiver operator characteristic curves ranging from 0.82 to 0.92 for cerebrospinal fluid and plasma metabolites, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Previous studies report Alzheimer\u2019s disease-associated soluble epoxide hydrolase upregulation in the brain and that endocannabinoid metabolism provides an adaptive response to neuroinflammation. This study supports the involvement of P450-dependent and endocannabinoid metabolism in Alzheimer\u2019s disease. The results further suggest that combined pharmacological intervention targeting both metabolic pathways may have therapeutic benefits for Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00893-6","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T08:03:19Z","timestamp":1630915399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3637-3450","authenticated-orcid":false,"given":"Kamil","family":"Borkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Lah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan I.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadwick M.","family":"Hales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Dammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Blach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Alzheimer\u2019s Disease Metabolomics Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"1","key":"893_CR1","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1038\/s41598-019-40630-6","volume":"9","author":"E Alkan","year":"2019","unstructured":"Alkan E, Taporoski TP, Sterr A, von Schantz M, Vallada H, Krieger JE, et al. Metabolic syndrome alters relationships between cardiometabolic variables, cognition and white matter hyperintensity load. Sci Rep. 2019;9(1):4356. https:\/\/doi.org\/10.1038\/s41598-019-40630-6.","journal-title":"Sci Rep."},{"key":"893_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3389\/fpsyt.2018.00647","volume":"9","author":"M Bosia","year":"2018","unstructured":"Bosia M, Buonocore M, Bechi M, Santarelli L, Spangaro M, Cocchi F, et al. Improving cognition to increase treatment efficacy in schizophrenia: effects of metabolic syndrome on cognitive remediation\u2019s outcome. Front Psychiatry. 2018;9:647. https:\/\/doi.org\/10.3389\/fpsyt.2018.00647.","journal-title":"Front Psychiatry."},{"issue":"6","key":"893_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41390-018-0229-z","volume":"85","author":"C Monthe-Dreze","year":"2019","unstructured":"Monthe-Dreze C, Rifas-Shiman SL, Gold DR, Oken E, Sen S. Maternal obesity and offspring cognition: the role of inflammation. Pediatr Res. 2019;85(6):799\u2013806. https:\/\/doi.org\/10.1038\/s41390-018-0229-z.","journal-title":"Pediatr Res."},{"issue":"5","key":"893_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3945\/an.114.007732","volume":"6","author":"M Gabbs","year":"2015","unstructured":"Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in our understanding of oxylipins derived from dietary PUFAs. Adv Nutr. 2015;6(5):513\u201340. https:\/\/doi.org\/10.3945\/an.114.007732.","journal-title":"Adv Nutr."},{"issue":"7","key":"893_CR5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/aps.2018.24","volume":"39","author":"MA Nayeem","year":"2018","unstructured":"Nayeem MA. Role of oxylipins in cardiovascular diseases. Acta Pharmacol Sin. 2018;39(7):1142\u201354. https:\/\/doi.org\/10.1038\/aps.2018.24.","journal-title":"Acta Pharmacol Sin."},{"issue":"1","key":"893_CR6","doi-asserted-by":"publisher","first-page":"8105","DOI":"10.1038\/s41598-020-65014-z","volume":"10","author":"CC Huang","year":"2020","unstructured":"Huang CC, Chang MT, Leu HB, Yin WH, Tseng WK, Wu YW, et al. Association of arachidonic acid-derived lipid mediators with subsequent onset of acute myocardial infarction in patients with coronary artery disease. Sci Rep. 2020;10(1):8105. https:\/\/doi.org\/10.1038\/s41598-020-65014-z.","journal-title":"Sci Rep."},{"issue":"4","key":"893_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.bpg.2014.07.004","volume":"28","author":"H Ma","year":"2014","unstructured":"Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):573\u201383. https:\/\/doi.org\/10.1016\/j.bpg.2014.07.004.","journal-title":"Best Pract Res Clin Gastroenterol."},{"issue":"7503","key":"893_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","volume":"510","author":"CN Serhan","year":"2014","unstructured":"Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92\u2013101. https:\/\/doi.org\/10.1038\/nature13479.","journal-title":"Nature."},{"issue":"3","key":"893_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0090-6980(92)90096-C","volume":"43","author":"I Schimke","year":"1992","unstructured":"Schimke I, Griesmacher A, Weigel G, Holzhutter HG, Muller MM. Effects of reactive oxygen species on eicosanoid metabolism in human endothelial cells. Prostaglandins. 1992;43(3):281\u201392. https:\/\/doi.org\/10.1016\/0090-6980(92)90096-C.","journal-title":"Prostaglandins."},{"issue":"6","key":"893_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1365-2826.2008.01728.x","volume":"20","author":"L Bellocchio","year":"2008","unstructured":"Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol. 2008;20(6):850\u20137. https:\/\/doi.org\/10.1111\/j.1365-2826.2008.01728.x.","journal-title":"J Neuroendocrinol."},{"key":"893_CR11","doi-asserted-by":"crossref","unstructured":"Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system.Int J Mol Sci. 2018;19(3):833.","DOI":"10.3390\/ijms19030833"},{"key":"893_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","volume":"160","author":"V Chiurchiu","year":"2018","unstructured":"Chiurchiu V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol. 2018;160:82\u2013100. https:\/\/doi.org\/10.1016\/j.pneurobio.2017.10.007.","journal-title":"Prog Neurobiol."},{"issue":"3","key":"893_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"3","author":"JY Chiang","year":"2013","unstructured":"Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191\u2013212. https:\/\/doi.org\/10.1002\/cphy.c120023.","journal-title":"Compr Physiol."},{"key":"893_CR14","first-page":"646","volume":"7","author":"C Guo","year":"2016","unstructured":"Guo C, Chen WD, Wang YD. TGR5, not only a metabolic regulator. Front Physiol. 2016;7:646.","journal-title":"Front Physiol."},{"key":"893_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0090-6980(02)00031-X","volume":"68-69","author":"NG Bazan","year":"2002","unstructured":"Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer\u2019s disease. Prostaglandins Other Lipid Mediat. 2002;68-69:197\u2013210.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"893_CR16","doi-asserted-by":"crossref","unstructured":"Kao YC, Ho PC, Tu YK, Jou IM, Tsai KJ. Lipids and Alzheimer\u2019s disease. IInt J Mol Sci. 2020;21(4):1505.","DOI":"10.3390\/ijms21041505"},{"key":"893_CR17","doi-asserted-by":"crossref","unstructured":"Miyazawa K, Fukunaga H, Tatewaki Y, Takano Y, Yamamoto S, Mutoh T, et al. Alzheimer\u2019s disease and specialized pro-resolving lipid mediators: do MaR1, RvD1, and NPD1 show promise for prevention and treatment? Int J Mol Sci. 2020;21(16):5783.","DOI":"10.3390\/ijms21165783"},{"issue":"1","key":"893_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","volume":"15","author":"S MahmoudianDehkordi","year":"2019","unstructured":"MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer\u2019s disease-an emerging role for gut microbiome. Alzheimers Dement. 2019;15(1):76\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.217.","journal-title":"Alzheimers Dement."},{"issue":"8","key":"893_CR19","doi-asserted-by":"publisher","first-page":"100138","DOI":"10.1016\/j.xcrm.2020.100138","volume":"1","author":"P Baloni","year":"2020","unstructured":"Baloni P, Funk CC, Yan J, Yurkovich JT, Kueider-Paisley A, Nho K, et al. Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer\u2019s disease. Cell Rep Med. 2020;1(8):100138. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100138.","journal-title":"Cell Rep Med."},{"key":"893_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fnagi.2016.00263","volume":"8","author":"HD Ackerman","year":"2016","unstructured":"Ackerman HD, Gerhard GS. Bile acids in neurodegenerative disorders. Front Aging Neurosci. 2016;8:263.","journal-title":"Front Aging Neurosci."},{"key":"893_CR21","doi-asserted-by":"publisher","unstructured":"Borkowski K, Taha AY, Pedersen TL, De Jager PL, Bennett DA, Kaddurah-Daouk R, et al. Serum metabolomic biomarkers of perceptual speed in cognitively normal and mildly impaired subjects with fasting state stratification. BioRxiv. . https:\/\/doi.org\/10.1101\/2020.09.03.282343.","DOI":"10.1101\/2020.09.03.282343"},{"issue":"3-4","key":"893_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000501856","volume":"53","author":"ME Goetz","year":"2019","unstructured":"Goetz ME, Hanfelt JJ, John SE, Bergquist SH, Loring DW, Quyyumi A, et al. Rationale and design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology. 2019;53(3-4):187\u2013200. https:\/\/doi.org\/10.1159\/000501856.","journal-title":"Neuroepidemiology."},{"issue":"4","key":"893_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403\u201313. https:\/\/doi.org\/10.1002\/ana.21610.","journal-title":"Ann Neurol."},{"issue":"8","key":"893_CR24","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52(8):1555\u201362. https:\/\/doi.org\/10.1212\/WNL.52.8.1555.","journal-title":"Neurology."},{"key":"893_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.aca.2020.11.019","volume":"1143","author":"TL Pedersen","year":"2021","unstructured":"Pedersen TL, Gray IJ, Newman JW. Plasma and serum oxylipin, endocannabinoid, bile acid, steroid, fatty acid and nonsteroidal anti-inflammatory drug quantification in a 96-well plate format. Anal Chim Acta. 2021;1143:189\u2013200. https:\/\/doi.org\/10.1016\/j.aca.2020.11.019.","journal-title":"Anal Chim Acta."},{"issue":"1","key":"893_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1194\/jlr.M071738","volume":"58","author":"K Agrawal","year":"2017","unstructured":"Agrawal K, Hassoun LA, Foolad N, Pedersen TL, Sivamani RK, Newman JW. Sweat lipid mediator profiling: a noninvasive approach for cutaneous research. J Lipid Res. 2017;58(1):188\u201395. https:\/\/doi.org\/10.1194\/jlr.M071738.","journal-title":"J Lipid Res."},{"key":"893_CR27","doi-asserted-by":"crossref","unstructured":"Saito K, Hattori K, Andou T, Satomi Y, Gotou M, Kobayashi H, et al. Characterization of postprandial effects on CSF metabolomics: a pilot study with parallel comparison to plasma.Metabolites. 2020;10(5):185.","DOI":"10.3390\/metabo10050185"},{"issue":"1","key":"893_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological). 1995;57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J Royal Stat Soc Ser B (Methodological)."},{"issue":"6","key":"893_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010956","volume":"5","author":"F Normand-Lauziere","year":"2010","unstructured":"Normand-Lauziere F, Frisch F, Labbe SM, Bherer P, Gagnon R, Cunnane SC, et al. Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. PLoS One. 2010;5(6):e10956. https:\/\/doi.org\/10.1371\/journal.pone.0010956.","journal-title":"PLoS One."},{"issue":"4","key":"893_CR30","doi-asserted-by":"publisher","first-page":"G300","DOI":"10.1152\/ajpgi.00157.2017","volume":"313","author":"J Fiamoncini","year":"2017","unstructured":"Fiamoncini J, Yiorkas AM, Gedrich K, Rundle M, Alsters SI, Roeselers G, et al. Determinants of postprandial plasma bile acid kinetics in human volunteers. Am J Physiol Gastrointest Liver Physiol. 2017;313(4):G300\u2013G12. https:\/\/doi.org\/10.1152\/ajpgi.00157.2017.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"10","key":"893_CR31","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/hmg\/ddl085","volume":"15","author":"CR Lee","year":"2006","unstructured":"Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet. 2006;15(10):1640\u20139. https:\/\/doi.org\/10.1093\/hmg\/ddl085.","journal-title":"Hum Mol Genet."},{"key":"893_CR32","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging I, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27:1034\u201342.","DOI":"10.1038\/s41591-021-01348-z"},{"issue":"2","key":"893_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/hep.29543","volume":"67","author":"D Jahn","year":"2018","unstructured":"Jahn D, Geier A. Bile acids in nonalcoholic steatohepatitis: pathophysiological driving force or innocent bystanders? Hepatology. 2018;67(2):464\u20136. https:\/\/doi.org\/10.1002\/hep.29543.","journal-title":"Hepatology."},{"key":"893_CR34","doi-asserted-by":"crossref","unstructured":"Grant SM, DeMorrow S. Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci. 2020;21(17):5982.","DOI":"10.3390\/ijms21175982"},{"issue":"10","key":"893_CR35","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","volume":"74","author":"SC Neu","year":"2017","unstructured":"Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178\u201389. https:\/\/doi.org\/10.1001\/jamaneurol.2017.2188.","journal-title":"JAMA Neurol."},{"key":"893_CR36","doi-asserted-by":"publisher","unstructured":"Ghosh A, Comerota ME, Wan D, Chen F, Propson NE, Hwang SH, et al. Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer\u2019s disease is resolved by a soluble epoxide hydrolase inhibitor. BioRxiv. . https:\/\/doi.org\/10.1101\/2020.06.30.180984.","DOI":"10.1101\/2020.06.30.180984"},{"key":"893_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biochi.2019.01.020","volume":"159","author":"SD Kodani","year":"2019","unstructured":"Kodani SD, Morisseau C. Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation. Biochimie. 2019;159:59\u201365. https:\/\/doi.org\/10.1016\/j.biochi.2019.01.020.","journal-title":"Biochimie."},{"issue":"2","key":"893_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/JAD-142349","volume":"46","author":"C Altamura","year":"2015","unstructured":"Altamura C, Ventriglia M, Martini MG, Montesano D, Errante Y, Piscitelli F, et al. Elevation of plasma 2-arachidonoylglycerol levels in Alzheimer\u2019s disease patients as a potential protective mechanism against neurodegenerative decline. J Alzheimers Dis. 2015;46(2):497\u2013506. https:\/\/doi.org\/10.3233\/JAD-142349.","journal-title":"J Alzheimers Dis."},{"issue":"4","key":"893_CR39","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s13311-020-00854-1","volume":"17","author":"C Grinan-Ferre","year":"2020","unstructured":"Grinan-Ferre C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, et al. Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer\u2019s disease. Neurotherapeutics. 2020;17(4):1825\u201335. https:\/\/doi.org\/10.1007\/s13311-020-00854-1.","journal-title":"Neurotherapeutics."},{"issue":"2","key":"893_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.yjmcc.2009.10.022","volume":"48","author":"Y Deng","year":"2010","unstructured":"Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol. 2010;48(2):331\u201341. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.10.022.","journal-title":"J Mol Cell Cardiol."},{"issue":"3","key":"893_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/FJC.0b013e318298e460","volume":"62","author":"A Ulu","year":"2013","unstructured":"Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, et al. Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013;62(3):285\u201397. https:\/\/doi.org\/10.1097\/FJC.0b013e318298e460.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"10","key":"893_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/nrd2875","volume":"8","author":"JD Imig","year":"2009","unstructured":"Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794\u2013805. https:\/\/doi.org\/10.1038\/nrd2875.","journal-title":"Nat Rev Drug Discov."},{"key":"893_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","volume":"180","author":"KM Wagner","year":"2017","unstructured":"Wagner KM, McReynolds CB, Schmidt WK, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther. 2017;180:62\u201376. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.006.","journal-title":"Pharmacol Ther."},{"issue":"1","key":"893_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sjbs.2014.09.003","volume":"22","author":"CK Firoz","year":"2015","unstructured":"Firoz CK, Jabir NR, Khan MS, Mahmoud M, Shakil S, Damanhouri GA, et al. An overview on the correlation of neurological disorders with cardiovascular disease. Saudi J Biol Sci. 2015;22(1):19\u201323. https:\/\/doi.org\/10.1016\/j.sjbs.2014.09.003.","journal-title":"Saudi J Biol Sci."},{"issue":"30","key":"893_CR45","doi-asserted-by":"publisher","first-page":"21618","DOI":"10.1074\/jbc.M113.481077","volume":"288","author":"EL Klett","year":"2013","unstructured":"Klett EL, Chen S, Edin ML, Li LO, Ilkayeva O, Zeldin DC, et al. Diminished acyl-CoA synthetase isoform 4 activity in INS 832\/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion. J Biol Chem. 2013;288(30):21618\u201329. https:\/\/doi.org\/10.1074\/jbc.M113.481077.","journal-title":"J Biol Chem."},{"issue":"2","key":"893_CR46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1006\/abbi.2000.1753","volume":"376","author":"JF Greene","year":"2000","unstructured":"Greene JF, Williamson KC, Newman JW, Morisseau C, Hammock BD. Metabolism of monoepoxides of methyl linoleate: bioactivation and detoxification. Arch Biochem Biophys. 2000;376(2):420\u201332. https:\/\/doi.org\/10.1006\/abbi.2000.1753.","journal-title":"Arch Biochem Biophys."},{"issue":"2","key":"893_CR47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/jnc.14818","volume":"152","author":"M Hennebelle","year":"2020","unstructured":"Hennebelle M, Morgan RK, Sethi S, Zhang Z, Chen H, Grodzki AC, et al. Linoleic acid-derived metabolites constitute the majority of oxylipins in the rat pup brain and stimulate axonal growth in primary rat cortical neuron-glia co-cultures in a sex-dependent manner. J Neurochem. 2020;152(2):195\u2013207. https:\/\/doi.org\/10.1111\/jnc.14818.","journal-title":"J Neurochem."},{"issue":"3","key":"893_CR48","first-page":"418","volume":"30","author":"H Takahashi","year":"1992","unstructured":"Takahashi H, Ishizaki T, Ameshima S, Kishi Y, Sasaki F, Nakai T, et al. Leukotoxin, 9,10-epoxy-12-octadecenoate, causes vasodilation in isolated pulmonary artery rings preconstricted with endothelin 1. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30(3):418\u201324.","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi."},{"key":"893_CR49","doi-asserted-by":"publisher","first-page":"108484","DOI":"10.1016\/j.jnutbio.2020.108484","volume":"86","author":"K Hildreth","year":"2020","unstructured":"Hildreth K, Kodani SD, Hammock BD, Zhao L. Cytochrome P450-derived linoleic acid metabolites EpOMEs and DiHOMEs: a review of recent studies. J Nutr Biochem. 2020;86:108484. https:\/\/doi.org\/10.1016\/j.jnutbio.2020.108484.","journal-title":"J Nutr Biochem."},{"issue":"5","key":"893_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm0597-562","volume":"3","author":"MF Moghaddam","year":"1997","unstructured":"Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med. 1997;3(5):562\u20136. https:\/\/doi.org\/10.1038\/nm0597-562.","journal-title":"Nat Med."},{"key":"893_CR51","doi-asserted-by":"publisher","first-page":"174480691666172","DOI":"10.1177\/1744806916661725","volume":"12","author":"D Green","year":"2016","unstructured":"Green D, Ruparel S, Gao X, Ruparel N, Patil M, Akopian A, et al. Central activation of TRPV1 and TRPA1 by novel endogenous agonists contributes to mechanical allodynia and thermal hyperalgesia after burn injury. Mol Pain. 2016;12:174480691666172. https:\/\/doi.org\/10.1177\/1744806916661725.","journal-title":"Mol Pain."},{"key":"893_CR52","doi-asserted-by":"publisher","unstructured":"Balleza-Tapia H, Crux S, Andrade-Talavera Y, Dolz-Gaiton P, Papadia D, Chen G, et al. TrpV1 receptor activation rescues neuronal function and network gamma oscillations from Abeta-induced impairment in mouse hippocampus in vitro. Elife. 2018;7. https:\/\/doi.org\/10.7554\/eLife.37703.","DOI":"10.7554\/eLife.37703"},{"issue":"3","key":"893_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13113","volume":"19","author":"Y Du","year":"2020","unstructured":"Du Y, Fu M, Huang Z, Tian X, Li J, Pang Y, et al. TRPV1 activation alleviates cognitive and synaptic plasticity impairments through inhibiting AMPAR endocytosis in APP23\/PS45 mouse model of Alzheimer\u2019s disease. Aging Cell. 2020;19(3):e13113. https:\/\/doi.org\/10.1111\/acel.13113.","journal-title":"Aging Cell."},{"key":"893_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fncel.2014.00195","volume":"8","author":"S Raboune","year":"2014","unstructured":"Raboune S, Stuart JM, Leishman E, Takacs SM, Rhodes B, Basnet A, et al. Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation. Front Cell Neurosci. 2014;8:195.","journal-title":"Front Cell Neurosci."},{"key":"893_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jnutbio.2019.03.004","volume":"68","author":"K Borkowski","year":"2019","unstructured":"Borkowski K, Yim SJ, Holt RR, Hackman RM, Keen CL, Newman JW, et al. Walnuts change lipoprotein composition suppressing TNFalpha-stimulated cytokine production by diabetic adipocyte. J Nutr Biochem. 2019;68:51\u20138. https:\/\/doi.org\/10.1016\/j.jnutbio.2019.03.004.","journal-title":"J Nutr Biochem."},{"issue":"7","key":"893_CR56","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","volume":"36","author":"RW Mahley","year":"2016","unstructured":"Mahley RW. Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arterioscler Thromb Vasc Biol. 2016;36(7):1305\u201315. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307023.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"893_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neulet.2015.03.024","volume":"593","author":"HC Yan","year":"2015","unstructured":"Yan HC, Kong YY, He BX, Huang MK, Li J, Zheng JQ, et al. CYP2J2 rs890293 polymorphism is associated with susceptibility to Alzheimer\u2019s disease in the Chinese Han population. Neuroscience Letters. 2015;593:56\u201360. https:\/\/doi.org\/10.1016\/j.neulet.2015.03.024.","journal-title":"Neuroscience Letters."},{"issue":"2","key":"893_CR58","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.abb.2004.05.003","volume":"427","author":"PK Srivastava","year":"2004","unstructured":"Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys. 2004;427(2):164\u20139. https:\/\/doi.org\/10.1016\/j.abb.2004.05.003.","journal-title":"Arch Biochem Biophys."},{"issue":"17","key":"893_CR59","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1523\/JNEUROSCI.0056-07.2007","volume":"27","author":"IP Koerner","year":"2007","unstructured":"Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci. 2007;27(17):4642\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.0056-07.2007.","journal-title":"J Neurosci."},{"key":"893_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.prostaglandins.2014.09.003","volume":"113-115","author":"JW Nelson","year":"2014","unstructured":"Nelson JW, Young JM, Borkar RN, Woltjer RL, Quinn JF, Silbert LC, et al. Role of soluble epoxide hydrolase in age-related vascular cognitive decline. Prostaglandins Other Lipid Mediat. 2014;113-115:30\u20137.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"2","key":"893_CR61","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41588-020-00773-z","volume":"53","author":"AP Wingo","year":"2021","unstructured":"Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer\u2019s disease pathogenesis. Nat Genet. 2021;53(2):143\u20136. https:\/\/doi.org\/10.1038\/s41588-020-00773-z.","journal-title":"Nat Genet."},{"issue":"6","key":"893_CR62","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1189\/jlb.3RU0115-021R","volume":"97","author":"C Turcotte","year":"2015","unstructured":"Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol. 2015;97(6):1049\u201370. https:\/\/doi.org\/10.1189\/jlb.3RU0115-021R.","journal-title":"J Leukoc Biol."},{"issue":"11","key":"893_CR63","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/bph.13580","volume":"174","author":"S Petrosino","year":"2017","unstructured":"Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349\u201365. https:\/\/doi.org\/10.1111\/bph.13580.","journal-title":"Br J Pharmacol."},{"issue":"2","key":"893_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/157015912800604515","volume":"10","author":"VM Saito","year":"2012","unstructured":"Saito VM, Rezende RM, Teixeira AL. Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol. 2012;10(2):159\u201366. https:\/\/doi.org\/10.2174\/157015912800604515.","journal-title":"Curr Neuropharmacol."},{"issue":"23","key":"893_CR65","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.2174\/138161208785740027","volume":"14","author":"T Bisogno","year":"2008","unstructured":"Bisogno T, Di Marzo V. The role of the endocannabinoid system in Alzheimer\u2019s disease: facts and hypotheses. Curr Pharm Des. 2008;14(23):2299\u20133305. https:\/\/doi.org\/10.2174\/138161208785740027.","journal-title":"Curr Pharm Des."},{"issue":"4","key":"893_CR66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/sj.bjp.0706093","volume":"144","author":"HB Bradshaw","year":"2005","unstructured":"Bradshaw HB, Walker JM. The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol. 2005;144(4):459\u201365. https:\/\/doi.org\/10.1038\/sj.bjp.0706093.","journal-title":"Br J Pharmacol."},{"issue":"8-9","key":"893_CR67","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.lfs.2012.11.008","volume":"92","author":"HB Bradshaw","year":"2013","unstructured":"Bradshaw HB, Raboune S, Hollis JL. Opportunistic activation of TRP receptors by endogenous lipids: exploiting lipidomics to understand TRP receptor cellular communication. Life Sci. 2013;92(8-9):404\u20139. https:\/\/doi.org\/10.1016\/j.lfs.2012.11.008.","journal-title":"Life Sci."},{"issue":"1","key":"893_CR68","doi-asserted-by":"publisher","first-page":"19064","DOI":"10.1038\/s41598-019-55452-9","volume":"9","author":"K Li","year":"2019","unstructured":"Li K, Luo X, Zeng Q, Jiaerken Y, Wang S, Xu X, et al. Interactions between sleep disturbances and Alzheimer\u2019s disease on brain function: a preliminary study combining the static and dynamic functional MRI. Sci Rep. 2019;9(1):19064. https:\/\/doi.org\/10.1038\/s41598-019-55452-9.","journal-title":"Sci Rep."},{"issue":"3","key":"893_CR69","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00702-008-0169-6","volume":"116","author":"D Koethe","year":"2009","unstructured":"Koethe D, Schreiber D, Giuffrida A, Mauss C, Faulhaber J, Heydenreich B, et al. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. J Neural Transm (Vienna). 2009;116(3):301\u20135. https:\/\/doi.org\/10.1007\/s00702-008-0169-6.","journal-title":"J Neural Transm (Vienna)."},{"key":"893_CR70","doi-asserted-by":"crossref","unstructured":"Giordano C, Plastina P, Barone I, Catalano S, Bonofiglio D. n-3 polyunsaturated fatty acid amides: new avenues in the prevention and treatment of breast cancer. Int J Mol Sci. 2020;21(7):2279.","DOI":"10.3390\/ijms21072279"},{"issue":"1","key":"893_CR71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10571-017-0554-5","volume":"38","author":"S Villapol","year":"2018","unstructured":"Villapol S. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell Mol Neurobiol. 2018;38(1):121\u201332. https:\/\/doi.org\/10.1007\/s10571-017-0554-5.","journal-title":"Cell Mol Neurobiol."},{"key":"893_CR72","doi-asserted-by":"publisher","first-page":"147135","DOI":"10.1016\/j.brainres.2020.147135","volume":"1749","author":"AJ Berry","year":"2020","unstructured":"Berry AJ, Zubko O, Reeves SJ, Howard RJ. Endocannabinoid system alterations in Alzheimer\u2019s disease: a systematic review of human studies. Brain Res. 2020;1749:147135.","journal-title":"Brain Res."},{"key":"893_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fphar.2014.00037","volume":"5","author":"E Aso","year":"2014","unstructured":"Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer\u2019s disease: moving toward the clinic. Front Pharmacol. 2014;5:37.","journal-title":"Front Pharmacol."},{"issue":"4","key":"893_CR74","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1021\/acs.jmedchem.0c01886","volume":"64","author":"BD Hammock","year":"2021","unstructured":"Hammock BD, McReynolds CB, Wagner K, Buckpitt A, Cortes-Puch I, Croston G, et al. Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative. J Med Chem. 2021;64(4):1856\u201372. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01886.","journal-title":"J Med Chem."},{"issue":"8","key":"893_CR75","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/j.1476-5381.2011.01445.x","volume":"165","author":"L Booker","year":"2012","unstructured":"Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol. 2012;165(8):2485\u201396. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01445.x.","journal-title":"Br J Pharmacol."},{"key":"893_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-7592-1_13","volume":"1730","author":"TL Pedersen","year":"2018","unstructured":"Pedersen TL, Newman JW. Establishing and performing targeted multi-residue analysis for lipid mediators and fatty acids in small clinical plasma samples. Methods Mol Biol. 2018;1730:175\u2013212.","journal-title":"Methods Mol Biol."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00893-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00893-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00893-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T08:16:44Z","timestamp":1630916204000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00893-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00893-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.09.21252423","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants from whom plasma and CSF samples were collected provided informed consent under protocols approved by the Institutional Review Board at Emory University. Cohorts included the Emory Healthy Brain Study (IRB00080300), Cognitive Neurology Research (IRB00078273), and Memory @ Emory (IRB00079069). All protocols were reviewed and approved by the Emory University Institutional Review Board. Ethics approval for metabolomics analysis: Analysis samples shipped from Emory were approved for metabolomic profiling and data analysis by the Institutional Review Board at Duke University (Pro00079616).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Dr. Kaddurah-Daouk is an inventor on several patents in the field of metabolomics and holds equity in Metabolon Inc. which was not involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}